Why Shares Of COVID-19 Vaccine Maker Moderna Are Shooting Higher On Monday

Shares of coronavirus vaccine maker Moderna Inc. MRNA were rallying in premarket trading on Monday.

What Happened: Jefferies analyst Michael Yee upgraded shares of Moderna from Neutral to Buy and raised the price target from $170 to $275, suggesting 42% upside from current levels.

The analyst sees the COVID-19 vaccine as no longer the thesis on the stock, with the consensus estimate for vaccine sales coming down from $20 billion in 2021-22 to $6 billion to $8 billion in 2023-24.

Moderna stock will likely go up in 2023, the analyst said, premising his deduction on the following factors:

  • New polycythemia vera cancer is the new story after last week’s positive Phase 2 data for its personalized cancer vaccine in skin cancer patients.
  • The Phase 3 respiratory syncytial vaccine data will likely be positive.
  • This will set the stage for combo vaccines with two to three antigens, which are all in Phase 2 stage and for which data readouts are expected in 2023.
  • Orphan disease franchise data is due in 2023.

“We see stock rebounding back up in 2023, a return of pipeline opportunities and a "story stock" as generalist and HC interest revisits the stock,” the analyst said.

Price Action: In premarket trading on Monday, Moderna shares were climbing 4.12%, to $201.26, according to Benzinga Pro data

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechLong IdeasNewsPre-Market OutlookAnalyst RatingsTrading IdeasCOVID-19 VaccineJefferiesMichael Yeewhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!